These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12004286)

  • 1. Intracellular carbovir triphosphate levels in patients taking abacavir once a day.
    Harris M; Back D; Kewn S; Jutha S; Marina R; Montaner JS
    AIDS; 2002 May; 16(8):1196-7. PubMed ID: 12004286
    [No Abstract]   [Full Text] [Related]  

  • 2. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
    Moyle G; Boffito M; Fletcher C; Higgs C; Hay PE; Song IH; Lou Y; Yuen GJ; Min SS; Guerini EM
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1532-8. PubMed ID: 19188387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.
    Pruvost A; Théodoro F; Agrofoglio L; Negredo E; Bénech H
    J Mass Spectrom; 2008 Feb; 43(2):224-33. PubMed ID: 17935070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interlaboratory measurement differences in intracellular carbovir triphosphate concentrations in HIV-infected patients: sources of variability in processing, shipping, and quantitation.
    Goicoechea M; Jain S; Bi L; Sun S; Smith G; Ha B; Richman D; Louie S; Haubrich R;
    J Clin Pharmacol; 2010 Aug; 50(8):968-74. PubMed ID: 19952374
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
    Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
    Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.
    Sleasman JW; Robbins BL; Cross SJ; Lindsey JC; Kraimer JM; Heckman BE; Sprenger HL; Tustin NB; Rose CH; Poston PA; Neal EF; Pakes GE; Nikanjam M; Capparelli EV
    Clin Pharmacol Ther; 2009 Apr; 85(4):394-401. PubMed ID: 19118380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved antiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carbovir 5'-triphosphate metabolite levels.
    Balzarini J; Aquaro S; Hassan-Abdallah A; Daluge SM; Perno CF; McGuigan C
    FEBS Lett; 2004 Aug; 573(1-3):38-44. PubMed ID: 15327972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir sulfate.
    Porche DJ
    J Assoc Nurses AIDS Care; 2000; 11(6):72-5. PubMed ID: 11082806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.
    Ray AS; Yang Z; Shi J; Hobbs A; Schinazi RF; Chu CK; Anderson KS
    Biochemistry; 2002 Apr; 41(16):5150-62. PubMed ID: 11955063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.
    Hoggard PG; Kewn S; Maherbe A; Wood R; Almond LM; Sales SD; Gould J; Lou Y; De Vries C; Back DJ; Khoo SH;
    AIDS; 2002 Dec; 16(18):2439-46. PubMed ID: 12461418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capillary electrophoresis-ion trap mass spectrometry analysis of Ziagen and its phosphorylated metabolites.
    Cai Z; Fung EN; Sinhababu AK
    Electrophoresis; 2003 Sep; 24(18):3160-4. PubMed ID: 14518039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.
    Capparelli EV; Letendre SL; Ellis RJ; Patel P; Holland D; McCutchan JA
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2504-6. PubMed ID: 15917556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.
    Falcinelli E; Francisci D; Belfiori B; Petito E; Guglielmini G; Malincarne L; Mezzasoma A; Sebastiano M; Conti V; Giannini S; Bonora S; Baldelli F; Gresele P
    Thromb Haemost; 2013 Aug; 110(2):349-57. PubMed ID: 23703656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily abacavir in place of twice-daily administration.
    Goedken AM; Herman RA
    Ann Pharmacother; 2005; 39(7-8):1302-8. PubMed ID: 15956231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases.
    White EL; Parker WB; Macy LJ; Shaddix SC; McCaleb G; Secrist JA; Vince R; Shannon WM
    Biochem Biophys Res Commun; 1989 Jun; 161(2):393-8. PubMed ID: 2472136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
    Gervasoni C; Vigano O; Grinelli E; Ortu M; Galli M; Rusconi S
    AIDS Patient Care STDS; 2007 Jan; 21(1):1-3. PubMed ID: 17263652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency.
    McGuigan C; Harris SA; Daluge SM; Gudmundsson KS; McLean EW; Burnette TC; Marr H; Hazen R; Condreay LD; Johnson L; De Clercq E; Balzarini J
    J Med Chem; 2005 May; 48(10):3504-15. PubMed ID: 15887959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women.
    Schalkwijk S; Colbers A; Konopnicki D; Weizsäcker K; Moltó J; Tenorio CH; Hawkins D; Taylor G; Wood C; van der Ende M; Burger D;
    AIDS; 2016 May; 30(8):1239-44. PubMed ID: 26836789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.